Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | RRM1 | P23921 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189550 | 0.82 | NR4A2 (0.39) | BRPF1NR4A2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27189569 | 0.76 | HTR1A (0.32) | HTR1ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25229209 | 0.75 | HTR2A (0.50) | NR4A2HTR1AALDH1A1NPSR1 | |
| SCHEMBL27189618 | 0.74 | MAPT (0.44) | SMN1; SMN2 | |
| SCHEMBL4393222 | 0.73 | HTR1A (0.40) | BRPF1HTR1ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25748082 | 0.70 | NR4A2 (0.36) | NR4A2ALDH1A1LMNANPSR1 | |
| SCHEMBL3613665 | 0.67 | BRPF1 (0.46) | BRPF1NR4A2ALDH1A1HPGD | |
| SCHEMBL27189565 | 0.67 | ALDH1A1 (0.30) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25029851 | 0.66 | HTR1A (0.72) | HTR1A | |
| SCHEMBL29761877 | 0.65 | KDM4E (0.50) | HTR1AALDH1A1LMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| CN-117897376-A | Heterocyclic compounds and process for preparing same | 光明智慧生物科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347561-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Bright Minds Biosciences Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022246554-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | OPRL1, OPRK1, CNR2 | BRPF1 3307/4885NR4A2 2617/4885HTR1A 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.